Seminar on thrombosis. Introduction.

J. Haft

Abstract:

What problem does this paper attempt to address?

Polarization of plasma membrane microviscosity during endothelial cell migration.

A. Vasanji,P. K. Ghosh,L. Graham,S. Eppell,P. Fox

DOI: https://doi.org/10.1016/S1534-5807(03)00397-6

IF: 13.417

Developmental Cell

Abstract:
Extracellular dextranase activity produced by human oral strains of the genus Bifidobacterium

A. Kaster,L. R. Brown

DOI: https://doi.org/10.1128/iai.42.2.716-720.1983

1983-11-01

Infection and Immunity

Abstract:Three strains of anaerobic, dextranase-producing, gram-positive, rod-shaped bacteria were isolated from human dental plaque associated with root carious lesions. The isolates produced a molar ratio of acetate to lactate from glucose fermentation ranging from 1.1 to 1.9. Each strain also produced fructose-6-phosphate phosphoketolase. The isolates were identified as belonging to the genus Bifidobacterium, but from their carbohydrate fermentation patterns they did not appear to be strains of Bifidobacterium dentium. These microorganisms fermented high-molecular-weight dextrans. A partial characterization of the dextranase activity was included in this study and revealed an extracellular dextranase with a pH optimum of 7.1. Analysis of the dextran degradation products demonstrated the liberation of saccharides larger than 1 glucose unit. It was concluded that this enzyme used an endohydrolytic mode of dextran cleavage.
1171 Hypersomnia Secondary to Long Covid

Dustin Peth,Sally Ibrahim

DOI: https://doi.org/10.1093/sleep/zsae067.01171

IF: 6.313

2024-04-20

SLEEP

Abstract:Abstract Introduction Recognition of Long Covid is increasing. In a recent meta-analysis in youth with Long Covid, the most prevalent clinical symptoms were mood (16.50%), fatigue (9.66%), and sleep disorders (8.42%). However, there is a paucity of data in the management of these symptoms. Report of case(s) We present a case of severe hypersomnolence after a mild Covid-19 infection in a 13 year-old female with no significant history, an acceptable age-appropriate sleep-wake schedule without nighttime awakenings or sleepiness prior to infection. Post-infection, she developed a one year history of sleep onset and maintenance insomnia, significant circadian delays, sleep inertia, brain fog and headaches. She was referred to sleep medicine and responded to treatment for a circadian rhythm disorder with sleep-wake restructuring, melatonin, and strict sleep hygiene. Sleep fragmentation, unrefreshing sleep, and hypersomnolence persisted; ESS=15/24. Sleep duration was often ≥12 hours in a 24 hour period. The patient could not wake easily, and often missed school or left early for sleepiness and headaches. A trial of gabapentin 200mg at bedtime failed. Sleep diagnostics were performed. Polysomnography showed no sleep disruptors, 8 hours of sleep, and some delayed slow wave sleep periods. Mean sleep latency testing (MSLT) showed MSL of 15.4min; 1 SOREM (nap #1). With a working diagnosis of hypersomnia due to medical condition vs. idiopathic hypersomnia, methylphenidate up to 36mg ER was trialed with some improvement. A recent adult case with Long Covid and ADHD-like syndrome also responded to stimulant use, though no guidelines are established for Long Covid. Oxybate was later added up to 2g once nightly which helped resolve sleep inertia, improve sleep quality and reduce sleepiness(ESS=4/24). She was able to return to school full time and reached normal functioning. Conclusion While the pathophysiology of Long Covid is still under investigation, symptom management of sleepiness can impact functioning. This case demonstrates a successful treatment of a patient with Long Covid and hypersomnolence with resolution of excessive sleepiness, morning inertia, and sleep fragmentation with a treatment approach similar to that of idiopathic hypersomnia, using an oxybate along with daytime stimulant use. Support (if any)

neurosciences,clinical neurology
Major depressive disorder with hypersomnolence complaint: A comparison study with non-depressed individuals examining objective biomarkers

Balthazar Bazin,Justine Frija-Masson,Helene Benzaquen,Julia Maruani,Jean-Arthur Micoulaud Franchi,Régis Lopez,Pierre Philip,Patrice Bourgin,Michel Lejoyeux,Marie-Pia d'Ortho,Pierre A Geoffroy,Pierre A. Geoffroy

DOI: https://doi.org/10.1016/j.jad.2024.02.056

IF: 6.533

2024-02-28

Journal of Affective Disorders

Abstract:Background Hypersomnolence is common in major depressive disorder (MDD), associated with more severe episodes, suicide and antidepressant resistance. Nevertheless, few studies used polysomnography (PSG) and multiple sleep latency test (MSLT) to characterize these patients. In this context, we compared patients visiting a sleep center for hypersomnolence complaint with MDD (HSC/MDD+) and without MDD (HSC/MDD-). Methods HSC/MDD+ and HSC/MDD- groups were defined according to DSM-5 criteria and CES-D scale, and had a 30 h-PSG with ad libitum -sleep and PSG followed by MLST. Results HSC/MDD+ had an increased self-declared total sleep time (sTST) of about 10 h30 similar to HSC/MDD- (630.8 ± 17.3 min- vs -616.5 ± 18.1 min, respectively, p = 0.39). Nevertheless, their objective TST (oTST) on ad libitum PSG was significantly longer and about 10 h50 (648.6 ± 23.9 min- vs -587.4 ± 19.0 min, respectively, p = 0.038). HSC/MDD+ also significantly better estimated their sleep duration, with a lower difference between their sTST and oTST compared to HSC/MDD- (10.0 ± 1.7 %- vs -17.4 ± 2.1 %, respectively, p = 0.009) and confirmed significantly more frequently the hypersomnia diagnosis - i.e. oTST>10H- (82.6 ± 8.1 %- vs -54.6 ± 10.9 %, respectively, p = 0.046). Using the Kupfer index (KI), we confirmed a reduced REM sleep latency in patients MDD/HSC+ (15.2 ± 10.0 %- vs -2.3 ± 2.3 %, respectively, p = 0.039). Both groups had comparable increased diurnal sleepiness assessed with the Epworth scale (14.1 ± 1.1- vs -14.8 ± 1.1, respectively, p = 0.65). HSC/MDD+ had less MSLT sleep latency <8 min (9.1 ± 5.1 %- vs -27.3 ± 6.8 %, respectively, p = 0.048). Limitations Retrospective cross-sectional study. Conclusions HSC/MDD+ accurately estimated their sleep duration, objectively confirmed hypersomnia and may specifically had a decreased Kupfer index.

psychiatry,clinical neurology
Multiple Sleep Latency Test/Maintenance of Wakefulness Test and Central Hypersomnias: Evolving Diagnostic and Therapeutic Approaches

Ajay C Sampat,Alon Y Avidan

DOI: https://doi.org/10.1097/WNP.0000000000000786

2023-03-01

Abstract:Central disorders of hypersomnolence include a spectrum of conditions, such as narcolepsy, idiopathic hypersomnia, and Kleine-Levin syndrome, in which excessive daytime sleepiness is the primary feature. Subjective testing with tools, such as sleep logs and sleepiness scales, are often helpful in the evaluation of these disorders but do not necessarily correlate well with objective testing, such as polysomnography and multiple sleep latency test and maintenance of wakefulness test. The most recent International Classification of Sleep Disorders-Third Edition has incorporated biomarkers, such as cerebrospinal fluid hypocretin level, into the diagnostic criteria and have restructured the classification of conditions based on our evolved understanding of their underlying pathophysiologic mechanisms. Therapeutic approaches largely consist of behavioral therapy, with a focus on optimizing sleep hygiene, optimizing opportunity for sleep, and strategic napping, along with judicious use of analeptic and anticataleptic agents when necessary. Emerging therapy has revolved around hypocretin-replacement therapy, immunotherapy, and nonhypocretin agents, with the goal of better targeting the underlying pathophysiology of these disorders rather than addressing symptoms. The most novel treatments have targeted the histaminergic system (pitolisant), dopamine reuptake transmission (solriamfetol), and gamma-aminobutyric acid modulation (flumazenil and clarithromycin) to promote wakefulness. Continued research is required for a more solid understanding of the biology of these conditions to develop a more robust armamentarium of therapeutic options.
Sleep, insomnia, and depression

Dieter Riemann,Lukas B. Krone,Katharina Wulff,Christoph Nissen

DOI: https://doi.org/10.1038/s41386-019-0411-y

2019-05-09

Neuropsychopharmacology

Abstract:Since ancient times it is known that melancholia and sleep disturbances co-occur. The introduction of polysomnography into psychiatric research confirmed a disturbance of sleep continuity in patients with depression, revealing not only a decrease in Slow Wave Sleep, but also a disinhibition of REM (rapid eye movement) sleep, demonstrated as a shortening of REM latency, an increase of REM density, as well as total REM sleep time. Initial hopes that these abnormalities of REM sleep may serve as differential-diagnostic markers for subtypes of depression were not fulfilled. Almost all antidepressant agents suppress REM sleep and a time-and-dose–response relationship between total REM sleep suppression and therapeutic response to treatment seemed apparent. The so-called Cholinergic REM Induction Test revealed that REM sleep abnormalities can be mimicked by administration of cholinomimetic agents. Another important research avenue is the study of chrono-medical timing of sleep deprivation and light exposure for their positive effects on mood in depression. Present day research takes the view on insomnia, i.e., prolonged sleep latency, problems to maintain sleep, and early morning awakening, as a transdiagnostic symptom for many mental disorders, being most closely related to depression. Studying insomnia from different angles as a transdiagnostic phenotype has opened many new perspectives for research into mechanisms but also for clinical practice. Thus, the question is: can the early and adequate treatment of insomnia prevent depression? This article will link current understanding about sleep regulatory mechanisms with knowledge about changes in physiology due to depression. The review aims to draw the attention to current and future strategies in research and clinical practice to the benefits of sleep and depression therapeutics.

pharmacology & pharmacy,neurosciences,psychiatry
Depressive symptoms in patients with hypersomnia measured with Beck Depression Inventory

Laura Datzer,Peter Geisler,Michael Roßkopf,Tatjana Crönlein

DOI: https://doi.org/10.1016/j.jpsychires.2024.09.014

Abstract:Background: Patients with central hypersomnia (HCO) often show symptoms of depression. Despite of many studies conducted in this field, the link between these two disorders remains unclear. In order to contribute data to this research, we examined the question of which depressive symptoms characterize these patients. Furthermore, we investigated the differences between HCO who were more or less depressed regarding insomnia, sleep quality and daytime tiredness. Methods and material: The retrospective analysis assesses the presence and kind of depressive symptoms as measured by the Beck Depression Inventory (BDI) in 168 HCO including narcolepsy type I (NAR1), narcolepsy type II (NAR2) and idiopathic hypersomnia (HYP). Sleep parameters from one night of polysomnography, scores of questionnaires for insomnia and for daytime sleepiness, and data from sustained attention tests were compared between HCO with and without depression, as determined by BDI scores (cut off >12). Results: According to BDI scores 52% exhibited no depression. The BDI items pertaining to tiredness and work inhibition exhibited elevated scores, whereas those pertaining to suicidality showed low scores. No difference was found between depressed and non-depressed HCO with regard to daytime vigilance performance or daytime sleepiness. However, depression was associated with older age, higher insomnia scores, and a shorter sleep time on polysomnography. Conclusion: A potential interpretation of our findings is that depressive symptoms in HCO may be a consequence of restricted life quality due to hypersomnia. Thus, therapeutical effort should focus more intensely on coping strategies.
Idiopathic Hypersomnia: Historical Account, Critical Review of Current Tests and Criteria, Diagnostic Evaluation in the Absence of Biological Markers and Robust Electrophysiological Diagnostic Criteria

Michel Billiard,Karel Sonka

DOI: https://doi.org/10.2147/NSS.S266090

2022-02-26

Abstract:Idiopathic hypersomnia was first described in 1976 under two forms: polysymptomatic, characterized by excessive daytime sleepiness, long and unrefreshing naps, nocturnal sleep of abnormally long duration and signs of sleep drunkenness upon awakening; monosymptomatic, manifested by excessive daytime sleepiness only. Yet, after 45 years, this sleep disorder is still poorly delineated and diagnostic criteria produced by successive International Classifications of Sleep Disorders are far from satisfactory. The first part of this review is a historical account of the successive names and descriptions of idiopathic hypersomnia: monosymptomatic and polysymptomatic idiopathic hypersomnia in 1976; central nervous system idiopathic hypersomnia in 1979; idiopathic hypersomnia in 1990; idiopathic hypersomnia with and without long sleep time in 2005; idiopathic hypersomnia again in 2014; and, within the last few years, the proposal of separating idiopathic hypersomnia into a well-defined subtype, idiopathic hypersomnia with long sleep duration, and a more heterogeneous subtype combining idiopathic hypersomnia without long sleep duration and narcolepsy type 2. The second part is a critical review of both current ICSD-3 diagnostic criteria and clinical features, scales and questionnaires, electrophysiological and circadian control tests, research techniques, currently used to diagnose idiopathic hypersomnia. The third part proposes a diagnostic evaluation of idiopathic hypersomnia, in the absence of biologic markers and of robust electrophysiological diagnostic criteria.
Excessive Daytime Sleepiness in Hypertensive Patients: The Role of Major Depressive Disorder

Alexandre Younes,Camille Point,Benjamin Wacquier,Jean-Pol Lanquart,Matthieu Hein

DOI: https://doi.org/10.3390/diagnostics14171854

IF: 3.6

2024-08-26

Diagnostics

Abstract:There is a special relationship between major depressive disorder and excessive daytime sleepiness. However, given the negative impact of excessive daytime sleepiness on life quality and cardiovascular outcome in hypertensive patients, the objective of this study was to investigate the potential role played by major depressive disorder in the occurrence of this complaint for this particular subpopulation. Data from 1404 hypertensive patients recruited from the Sleep Unit's polysomnographic recordings database were analyzed. A score >10 on the Epworth Sleepiness Scale was used to define excessive daytime sleepiness in this study. Logistic regression analyses were performed to investigate the risk of excessive daytime sleepiness associated with major depressive disorder in hypertensive patients. Excessive daytime sleepiness was frequent (40.0%) in our sample of hypertensive patients. After adjustments for major confounding factors, multivariate logistic regression analyses demonstrated that unlike remitted major depressive disorder, only current major depressive disorder was associated with a higher risk of excessive daytime sleepiness in hypertensive patients. Given this potential implication of current major depressive disorder in the occurrence of excessive daytime sleepiness for hypertensive patients, it is therefore essential to achieve the complete remission of this psychiatric disorder to avoid negative consequences associated with this complaint in this particular subpopulation.

medicine, general & internal
French consensus. Hypersomnolence: Evaluation and diagnosis

Y Dauvilliers,R Lopez,M Lecendreux

DOI: https://doi.org/10.1016/j.neurol.2016.09.017

Abstract:Sleepiness is one of the most frequently reported complaints in adults and children during specialised sleep consultations. It is responsible for an alteration that can be severe in quality of life, a lowering of academic or professional performance, and domestic or work accidents. Hypersomnolence is the first cause of road accidents on the highway, responsible for a third of fatal accidents. Furthermore its presence is associated with an increased risk of morbi-mortality related to cardiovascular and neurodegenerative pathologies. Hence, its represents a real public health issue. Recent revisions in international classifications have clarified confusing terminology, and the complaint of hypersomnia has now been replaced by the terms hypersomnolence or excessive sleepiness. It is clinically defined as an excessive quantity of sleep over 24hours, and/or by an alteration in the quality of arousal defined as incapacity to maintain a satisfactory level of vigilance during the day or in the morning on awakening (defined as sleep inertia). The evaluation of sleepiness requires a rigorous clinical approach, completed by subjective and objective measurements. The Epworth Sleep Scale, Multiple Sleep Latency Tests and the Maintenance of Wakefulness Test are the most studied and used in clinical practice. However, to date, no gold standard measurement of excessive sleepiness exists, and there are no quantifiable biological markers. It is therefore important to optimise our evaluation tools, improve our pathophysiological understanding of sleepiness, and define genetic and environmental risk factors.
Narcolepsy and Other Central Hypersomnias

Yves Dauvilliers,Lucie Barateau

DOI: https://doi.org/10.1212/CON.0000000000000492

Abstract:Purpose of review: This article focuses on the clinical presentation, pathophysiology, diagnosis, differential diagnosis, and management of narcolepsy type 1 and narcolepsy type 2, idiopathic hypersomnia, Kleine-Levin syndrome, and other central disorders of hypersomnolence, as defined in the International Classification of Sleep Disorders, Third Edition (ICSD-3). Recent findings: In ICSD-3, the names of some central disorders of hypersomnolence have been changed: narcolepsy with cataplexy and narcolepsy without cataplexy have been renamed narcolepsy type 1 and narcolepsy type 2, respectively. A low level of hypocretin-1/orexin-A in the CSF is now theoretically sufficient to diagnose narcolepsy type 1, as it is a highly specific and sensitive biomarker. Conversely, other central hypersomnias are less well-defined disorders with variability in the phenotype, and few reliable biomarkers have been discovered so far. The epidemiologic observation that influenza A (H1N1) infection and vaccination are potential triggering factors of narcolepsy type 1 (discovered during the 2009 H1N1 pandemic) has increased interest in this rare disease, and progress is being made to better understand the process (highly suspected to be autoimmune) responsible for the destruction of hypocretin neurons. Treatment of narcolepsy remains largely symptomatic, usually initially with modafinil or armodafinil or with higher-potency stimulants such as methylphenidate or amphetamines. Several newer wake-promoting agents and psychostimulants have also been developed, including sodium oxybate, which has a role in the treatment of cataplexy and as an adjunctive wake-promoting agent, and pitolisant, a selective histamine H3 receptor inverse agonist that is currently only available in Europe. Summary: Although far less common than many other sleep disorders, central hypersomnias are among the most severe and disabling diseases in the field of sleep medicine, and their early recognition is of major importance for patients, especially children, to maximize their quality of life and functioning in activities of daily living.
Insomnia in Patients with Depression

Ripu D. Jindal

DOI: https://doi.org/10.2165/00023210-200923040-00004

2009-01-01

CNS Drugs

Abstract:The almost ubiquitous sleep disturbances in patients with depression commonly, but not always, subside with the remission of depression. Evidence linking insomnia with the risk of relapses in recurrent depression, as well as suicide, makes optimization of the treatment of insomnia associated with depression a priority. However, most antidepressant agents do not adequately address the sleep complaints in depression: their effects on sleep range from sizeable improvement to equally significant worsening. One approach to the management of insomnia associated with depression is to choose a sedating antidepressant agent such as trazodone, mirtazapine or agomelatine. A second approach is to start with a non-sedating antidepressant (e.g. the selective serotonin reuptake inhibitors, bupropion, venlafaxine or duloxetine); those with a persistent or treatment-emergent insomnia can be switched to a more sedating antidepressant, or offered a hypnotic or cognitive-behavioural therapy as adjunctive treatment. The review discusses the advantages and disadvantages of all treatment options, pharmacological and otherwise

pharmacology & pharmacy,psychiatry,clinical neurology
Insomnia in ambulatory care: A clinical review

Julie A Dopheide,Winter Rayne Nicole Roth,Michelle Chu

DOI: https://doi.org/10.1093/ajhp/zxae255

2024-09-26

Abstract:Disclaimer: In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time. Purpose: One-third to one-half of ambulatory care patients report insomnia. The objective of this clinical review is to detail the many causes and evidence-based treatment options for insomnia in outpatients and to recommend screening and summarize evidence for the place in therapy of prescription and nonprescription treatments. Summary: This work provides an overview of the literature on insomnia regarding causes, patient assessment, and nonpharmacological and pharmacological treatments. Patients who present with insomnia should be assessed for sleep apnea, restless legs syndrome, narcolepsy, and all contributing medications as well as medical, psychiatric, and substance use disorder diagnoses. The type of insomnia, namely difficulty falling asleep, difficulty maintaining sleep, and early morning awakening with resulting functional impairment, should be documented in addition to whether insomnia is short term or persistent. Cognitive behavioral therapy for insomnia (CBT-I) or digital CBT-I is first-line treatment for all patients with insomnia irrespective of the cause or type. Nonprescription treatments such as antihistamines or melatonin are for select populations. Prescription hypnotics are best utilized on an as-needed basis or for nightly use for less than 6 weeks. Z-hypnotics are safe and effective for insomnia in persons with depression or an anxiety disorder but should be avoided in older individuals or if there is respiratory or cognitive impairment. Orexin receptor antagonists are effective for sleep initiation and maintenance in healthy persons or if there is mild cognitive impairment, but they require further study in individuals with psychiatric and medical diagnoses. Trazodone is the most prescribed off-label treatment due to its efficacy for sleep initiation and maintenance and its lack of abuse potential. Conclusion: Insomnia treatment should be guided by patient age, diagnoses, and type of insomnia. Pharmacological treatments should be used at the lowest effective dose for the shortest duration of time.
Post-COVID central hypersomnia, a treatable trait in long COVID: 4 case reports

Clémence Morelli-Zaher,Andrea Vremaroiu-Coman,Nicolas Coquoz,Léon Genecand,Marco Altarelli,Alzbeta Binkova,Isabelle Frésard,Pierre-Olivier Bridevaux,Grégoire Gex

DOI: https://doi.org/10.3389/fneur.2024.1349486

IF: 3.4

2024-02-14

Frontiers in Neurology

Abstract:Introduction Fatigue is the most commonly reported post-COVID symptom. A minority of patients also report excessive daytime sleepiness, which could be a target for treatment. Methods Among 530 patients with a post-COVID condition, those with excessive daytime sleepiness were systematically assessed for objective central hypersomnia, with exclusion of all cases not clearly attributable to SARS-CoV-2 infection. Results Four cases of post-COVID central hypersomnia were identified, three fulfilling the criteria of the 3rd International Classification of Sleep Disorders for idiopathic hypersomnia, and one for type II narcolepsy. We report here their clinical history, sleep examination data and treatment, with a favorable response to methylphenidate in three cases and spontaneous resolution in one case. Conclusion We highlight the importance of identifying cases of post-COVID central hypersomnia, as it may be a treatable trait of a post-COVID condition.

neurosciences,clinical neurology
Alertness in patients with treatment-resistant depression: interface between sleep medicine and psychiatry—review article

Dusan Kolar,Michael V. Kolar

DOI: https://doi.org/10.1186/s43045-021-00124-6

2021-07-14

Middle East Current Psychiatry

Abstract:Abstract Background Treatment-resistant depression (TRD) is a significant problem in clinical practice and reason for the lack of functional recovery among depressed patients. Sleep disturbances and poor alertness are common residual symptoms. Main body of the abstract Many patients with refractory depression experience residual symptoms, such as insomnia, daytime sleepiness, and poor alertness. This is a literature review and we searched the electronic databases, including PubMed, the Cochrane database, Ovid MEDLINE, PsycINFO, and Google Scholar of all studies published between 2000 and 2020. The literature on the relationship between sleep quality and alertness in a patient with depression is very sparse. One possible reason could be the difficulty in defining alertness as a mental function. Alertness itself has been described as a state of responsivity to both interoceptive and external stimuli. Subjective and objective measures of alertness, daytime somnolence, and quality of sleep are presented. Adjunctive treatment with stimulant medications (methylphenidate, amphetamine, modafinil) to the standard antidepressant medications might be warranted in patients in patients with daytime sleepiness, decreased alertness, fatigue, and poor work performance. Short conclusion Patients with treatment-resistant depression usually suffer from poor quality of sleep and decreased alertness. Stimulant medications may help with alertness, daily functioning, and work performance.
Insomnia Management: A Review and Update

David P Shaha

DOI: https://doi.org/10.12788/jfp.0620

Abstract:Insomnia is a distinct disorder that is common, yet underrecognized and undertreated in primary care. Treating insomnia has been shown to improve outcomes, including reduced risk of developing cardiovascular and mental health disorders. Insomnia is influenced by the brain's regulation of sleep and wake, which are mutually exclusive events. Insomnia should be treated as a distinct condition, even when occurring with a comorbid diagnosis such as depression or anxiety. Clinicians should implement a multimodal approach to insomnia management, including nonpharmacologic interventions and pharmacologic therapy (when indicated). Pharmacologic agents that are approved by the US Food and Drug Administration for insomnia include benzodiazepine receptor agonists (zolpidem, eszopiclone, and zaleplon), low-dose doxepin (tricyclic antidepressant), ramelteon (melatonin receptor agonist), and dual orexin receptor agonists (DORAs, daridorexant, lemborexant, and suvorexant). Unlike other pharmacologic agents, DORAs inhibit wakefulness rather than induce sedation. Additionally, these medications have no evidence of rebound insomnia or withdrawal, and little to no abuse potential. Daridorexant is the newest DORA, has an ideal half-life of 8 hours, and has demonstrated continued efficacy over a 12-month period. Selection of pharmacologic agent should be based on the patient's comorbid conditions, treatment goals and preferences, and other clinical characteristics.
Histopathological and histochemical analysis of trabeculectomy specimens in open angle and steroid induced glaucoma--a clinicopathological study.

N. Sood,A. R. Raghu Ram

Indian Journal of Ophthalmology

Abstract:
Answering Developmental Questions Using Secondary Data.

P. Davis‐Kean,Justin Jager,J. Maslowsky

DOI: https://doi.org/10.1111/CDEP.12151

IF: 6.16

2015-12-01

Child Development Perspectives

Abstract:Secondary data analysis of large longitudinal and national data sets is a standard method used in many social sciences to answer complex questions regarding behavior. In this article, we detail the advantages of using these data sets to study developmental questions across the lifespan. First, we provide an overview of how using secondary data can increase studies' scientific integrity. Then, we detail where and how data sets can be obtained that answer specific questions. Finally, we discuss methodological issues related to using longitudinal, population data sets. These data sets can enhance science and test theories by increasing the rigor and generalizability of research to the general population, making secondary data analysis an important method to consider.
Evaluating pharmacological treatments for excessive daytime sleepiness in obstructive sleep apnea: A comprehensive network meta-analysis and systematic review

Seyed Sina Neshat,Afshin Heidari,Mario Henriquez-Beltran,Kripa Patel,Brendon Colaco,Vichaya Arunthari,Alejandra Yu Lee Mateus,Joseph Cheung,Gonzalo Labarca

DOI: https://doi.org/10.1016/j.smrv.2024.101934

Abstract:Obstructive sleep apnea (OSA) is associated with excessive daytime sleepiness (EDS). Pharmacotherapy offers a potential treatment approach for EDS in OSA patients. This systematic review and meta-analysis aimed to assess the efficacy and safety of pharmacological interventions for alleviating EDS in patients with OSA. Following PRISMA guidelines, we included randomized controlled trials investigating pharmacological treatments for EDS in adult OSA until August 2023. We conducted meta-analysis, subgroup, and meta-regression analyses using a random effects model. Finally, a network meta-analysis synthesized direct and indirect evidence, followed by a comprehensive safety analysis. We included 32 articles in the meta-analysis (n = 3357). Pharmacotherapy showed a significant improvement in the Epworth Sleepiness Scale (ESS) score (Mean Difference (MD) -2.73, (95 % Confidence Interval (CI) [-3.25, -2.20], p < 0.01) and Maintenance of Wakefulness Test (MWT) score (MD 6.00 (95 % CI [2.66, 9.33] p < 0.01). Solriamfetol, followed by Pitolisant and modafinil, exhibited the greatest ESS reduction, while Danavorexton, followed by Solriamfetol and MK-7288, had the strongest impact on MWT. MK-7288 had the most total adverse events (AEs), followed by Danavorexton and armodafinil. Pharmacological Interventions significantly alleviate EDS in OSA patients but with heterogeneity across medications. Treatment decisions should involve a personalized assessment of patient factors and desired outcomes.
Residual excessive daytime sleepiness in patients treated for obstructive sleep apnea: guidance for assessment, diagnosis, and management

Russell Rosenberg,Paula K. Schweitzer,Joerg Steier,Jean-Louis Pepin

DOI: https://doi.org/10.1080/00325481.2021.1948305

2021-07-22

Postgraduate Medicine

Abstract:Excessive daytime sleepiness (EDS) affects approximately half of patients with obstructive sleep apnea (OSA) and can persist in some despite normalization of breathing, oxygenation, and sleep quality with primary OSA therapy, such as continuous positive airway pressure (CPAP). EDS is often overlooked and under discussed in the primary care setting and in the follow-up of CPAP-treated patients due to difficult assessment of such a multi-dimensional symptom. This review aims to provide suggestions for procedures that can be implemented into routine clinical practice to identify, evaluate, and manage EDS in patients treated for OSA, including how to appropriately use various self-report and objective assessments along the clinical pathway and options for pharmacotherapy. In addition, examples of when it is appropriate to refer a patient to a sleep specialist for evaluation are discussed.

medicine, general & internal

Seminar on thrombosis. Introduction.

Polarization of plasma membrane microviscosity during endothelial cell migration.

Extracellular dextranase activity produced by human oral strains of the genus Bifidobacterium

1171 Hypersomnia Secondary to Long Covid

Major depressive disorder with hypersomnolence complaint: A comparison study with non-depressed individuals examining objective biomarkers

Multiple Sleep Latency Test/Maintenance of Wakefulness Test and Central Hypersomnias: Evolving Diagnostic and Therapeutic Approaches

Sleep, insomnia, and depression

Depressive symptoms in patients with hypersomnia measured with Beck Depression Inventory

Idiopathic Hypersomnia: Historical Account, Critical Review of Current Tests and Criteria, Diagnostic Evaluation in the Absence of Biological Markers and Robust Electrophysiological Diagnostic Criteria

Excessive Daytime Sleepiness in Hypertensive Patients: The Role of Major Depressive Disorder

French consensus. Hypersomnolence: Evaluation and diagnosis

Narcolepsy and Other Central Hypersomnias

Insomnia in Patients with Depression

Insomnia in ambulatory care: A clinical review

Post-COVID central hypersomnia, a treatable trait in long COVID: 4 case reports

Alertness in patients with treatment-resistant depression: interface between sleep medicine and psychiatry—review article

Insomnia Management: A Review and Update

Histopathological and histochemical analysis of trabeculectomy specimens in open angle and steroid induced glaucoma--a clinicopathological study.

Answering Developmental Questions Using Secondary Data.

Evaluating pharmacological treatments for excessive daytime sleepiness in obstructive sleep apnea: A comprehensive network meta-analysis and systematic review

Residual excessive daytime sleepiness in patients treated for obstructive sleep apnea: guidance for assessment, diagnosis, and management